November 21, 2016 - By Marie Mckinney · 0 Comments
Prophase Labs Inc (NASDAQ:PRPH) institutional sentiment decreased to 0.5 in 2016 Q2. Its down -1.17, from 1.67 in 2016Q1. The ratio fall, as 5 investment managers started new or increased positions, while 3 sold and reduced holdings in Prophase Labs Inc. The investment managers in our partner’s database now possess: 1.11 million shares, down from 1.16 million shares in 2016Q1. Also, the number of investment managers holding Prophase Labs Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 3 Increased: 3 New Position: 2.
ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a range of homeopathic and health products. The company has a market cap of $33.83 million. The Firm is also engaged in the research and development of over-the-counter drugs, natural base health products along with supplements, personal care and cosmeceutical products. It currently has negative earnings. It is engaged in manufacturing, distributing, marketing and sale of OTC cold remedy products to clients through national chain, regional, specialty and local retail stores.
The stock decreased 0.99% or $0.02 on November 18, hitting $2.01. ProPhase Labs Inc (NASDAQ:PRPH) has risen 47.79% since April 19, 2016 and is uptrending. It has outperformed by 43.93% the S&P500.
According to Zacks Investment Research, “ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company’s mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZEÂ®, a zinc gluconate glycine product. COLD-EEZEÂ® family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.”
ProPhase Labs, Inc., incorporated on August 24, 1989, is a manufacturer, marketer and distributor of a range of homeopathic and health products. The Firm is also engaged in the research and development of over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. The Company’s primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to clients through national chain, regional, specialty and local retail stores. The Firm also makes, markets and distributes an organic cough drop and a Vitamin C supplement, Organix, and performs contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties.
More notable recent ProPhase Labs Inc (NASDAQ:PRPH) news were published by: Finance.Yahoo.com which released: “ProPhase Labs Reports Arbitration Decision In Phusion Laboratories …” on November 16, 2016, also Seekingalpha.com with their article: “ProPhase Labs: One Hit Wonder Or About To Explode?” published on June 21, 2016, Streetinsider.com published: “Form 8-K ProPhase Labs, Inc. For: Nov 14” on November 15, 2016. More interesting news about ProPhase Labs Inc (NASDAQ:PRPH) were released by: Marketwired.com and their article: “ProPhase Labs to Release Second Quarter 2016 Results on Tuesday, August 9th” published on August 05, 2016 as well as Philly.com‘s news article titled: “Cold-Eeze CEO speaks about firm’s new male sex drive pill” with publication date: January 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney